While systemic pharmacodynamic activity of JNJ-77242113 was observed in blood from healthy volunteers, it is unknown how this activity will translate to efficacy in different disease states as unique dose regimens are required for currently approved anti–IL-23 antibodies in psoriasis and psoriatic arthritis compared to Crohn’s disease3,30–32. This evidence concerns the gene IL23A and psoriasis.